126 related articles for article (PubMed ID: 18779749)
1. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses.
Linnebacher M; Maletzki C; Emmrich J; Kreikemeyer B
J Immunother; 2008 Oct; 31(8):704-13. PubMed ID: 18779749
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model.
Maletzki C; Linnebacher M; Kreikemeyer B; Emmrich J
Gut; 2008 Apr; 57(4):483-91. PubMed ID: 18025068
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells.
Bae SM; Kim YW; Kwak SY; Kim YW; Ro DY; Shin JC; Park CH; Han SJ; Oh CH; Kim CK; Ahn WS
Cancer Sci; 2007 May; 98(5):747-52. PubMed ID: 17425690
[TBL] [Abstract][Full Text] [Related]
4. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
5. Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma.
Eisold S; Schmidt J; Ryschich E; Gock M; Klar E; von Knebel Doeberitz M; Linnebacher M
Pancreas; 2007 Jul; 35(1):63-72. PubMed ID: 17575547
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
9. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor immunity of dendritic cells pulsed with heat-treated tumor lysate in murine pancreatic cancer.
Kim HS; Choo YS; Koo T; Bang S; Oh TY; Wen J; Song SY
Immunol Lett; 2006 Mar; 103(2):142-8. PubMed ID: 16313973
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
[TBL] [Abstract][Full Text] [Related]
14. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
15. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
16. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.
Schmitz-Winnenthal FH; Volk C; Z'graggen K; Galindo L; Nummer D; Ziouta Y; Bucur M; Weitz J; Schirrmacher V; Büchler MW; Beckhove P
Cancer Res; 2005 Nov; 65(21):10079-87. PubMed ID: 16267034
[TBL] [Abstract][Full Text] [Related]
17. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
19. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
20. Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids.
Ziske C; Etzrodt PE; Eliu AS; Gorschlüter M; Strehl J; Flieger D; Messmer D; Schmitz V; Gonzalez-Carmona MA; Sievers E; Brossart P; Sauerbruch T; Schmidt-Wolf IG
Pancreas; 2009 Oct; 38(7):758-65. PubMed ID: 19546834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
